Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00437216 · ClinicalTrials.gov registry record
Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis
A clinical trial, sponsored by Galderma R&D.
- Completed
- Registry status
- 2,488
- Enrollment target
NCT00437216: Completed study, sponsored by Galderma R&D.
NCT00437216 is a clinical trial that has completed, run by Galderma R&D. The registered enrollment target is 2,488 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00437216 has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- 2,488 participants
- Enrollment target
Study Summary
Evaluation of the effectiveness of Clobex® Spray, 0.05% when used as monotherapy or add-on therapy to existing systemic or topical anti-psoriatic agents.
Interventions
- DRUG Clobetasol Propionate, 0.05%
- DRUG Clobetasol propionate, 0.05% Spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,488 participants |
| Start Date | 2006-02 |
| Est. Completion | 2006-07 |
What the finished NCT00437216 record still lists
NCT00437216 is an observational study that tracks outcomes without assigning an intervention. Its 2,488 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Clobetasol Propionate, 0.05% is the first listed.
NCT00437216 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00437216 about?
NCT00437216 is a clinical study titled "Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis". Evaluation of the effectiveness of Clobex® Spray, 0.05% when used as monotherapy or add-on therapy to existing systemic or topical anti-psoriatic agents.
What is the current status of trial NCT00437216?
This trial is currently completed. The enrollment target is 2,488 participants. The study started on 2006-02. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00437216?
The interventions under investigation include: Clobetasol Propionate, 0.05% (DRUG), Clobetasol propionate, 0.05% Spray (DRUG).
Who is sponsoring clinical trial NCT00437216?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
- NCT01904188 · 2,500 participants
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
- NCT02257229 · 2,500 participants
Prospective Evaluation of Treatment for Clubfoot
- NCT02530658 · 2,500 participants
Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia